Abbvie to submit first Genmab collaboration candidate in 2022

According to Genmab-partner Abbvie, the two companies are close to filing for marketing approval for epcoritamab, a potential treatment for lymphoma.

Jan van de Winkel, CEO at Genmab | Photo: Stine Bidstrup/Ritzau Scanpix

Genmab and its partner, Abbvie, will soon be ready to submit epcoritamab for marketing authorization as a treatment of the cancer type diffuse large B-cell lymphoma (DLCBL)

The application concerns the treatment of patients with relapsed or refractory cancer, a pipeline update from Abbvie reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs